NEW YORK, Nov. 26 /PRNewswire/ -- Dr. Dennis Giesing, Chief Scientific Officer and Terry Nida, Chief Operating Officer of Urigen Pharmaceuticals, Inc. (OTC Bulletin Board: URGP) (http://www.urigen.com) will be featured in an exclusive interview with http://www.wallst.net scheduled for November 27 at 10:30 a.m. EST. The interview will be posted on http://www.wallst.net by 8 p.m. EST on November 27.
The interview will cover topics including Urigen Pharmaceutical's market potential, growth initiatives, competitive edge, recent news, and milestones for which investors should watch.
To hear the interview in its entirety, visit http://www.wallst.net and click on "Interviews." The interview can be accessed by locating the company's ticker symbol under the appropriate exchange at the top of the "Interviews" section or by entering the company's ticker symbol in the Search Archive window.
About Urigen Pharmaceuticals:
Urigen Pharmaceuticals is a specialty pharmaceutical company dedicated to the development and commercialization of therapeutic products for urological disorders. Urigen's two lead programs target significant unmet medical needs and major market opportunities in urology. Urigen's URG101 project targets painful bladder syndrome/interstitial cystitis, which affects approximately 10.5 million men and women in North America. Urigen's URG301 project targets acute urgency in patients diagnosed with an overactive bladder, another major unmet need that is insufficiently managed by presently available overactive bladder drugs. URG301 is a proprietary dosage form of an approved drug that is locally delivered to control urinary urgency.
For further information, please visit Urigen's website at http://www.urigen.com.
http://www.wallst.net is owned and operated by WallStreet Direct, Inc., a wholly owned subsidiary of Financial Media Group, Inc. The Website is a leading provider of timely business news, executive interviews, multimedia content, and research tools. Financial Media Group, Inc. also owns http://www.mywallst.net, a financial social network for investors, Financial Filings Corp., a provider of compliance solutions to publicly traded companies, and WallStRadio, a business and finance podcast Website. Financial Filings Corp. is expecting to receive two hundred eighty dollars from Urigen Pharmaceuticals, Inc. for the dissemination of this press release. For a complete list of our advertisers and advertising relationships, visit http://www.wallst.net/disclaimer/disclaimer.asp.
|SOURCE Financial Filings Corp.|
Copyright©2007 PR Newswire.
All rights reserved